Dr. M stated this about Sgi-110. Clearly this is a concern that sgi-110 impacts only a small percentage of responses. They are trying everything to make this drug work better. 10 day and 90 MG. I still believe this is overvalued. It was much safer to own it in the $2's than anyone paying $5.50 for it. At-13387 still looks interesting.
They added another trial in LEE-011 by novatis, however will not begin enrolling till August. I would risk funds at $3.75 range, do not see anything that would pop this. Think dr. m hinted at dacogen in aml in Japan. Milestones wear off quickly, so if they do get a milestone this year, it's a non event as far as I'm concerned. Dr. M did state they haven't seen word on generic dacogen. The value isn't with dacogen, it's in the pipeline and right now two many balls in the air and nothing really jumping out on pipeline.
I suggest you wait for a real pullback and get shares for free with profits.